{"nctId":"NCT01030822","briefTitle":"Booster and Catch-up Vaccination With Vaccine GSK1024850A","startDateStruct":{"date":"2010-04-02"},"conditions":["Infections, Streptococcal"],"count":282,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal vaccine GSK1024850A"]},{"label":"Group B","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal vaccine GSK1024850A"]},{"label":"Group C","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal vaccine GSK1024850A"]}],"interventions":[{"name":"Pneumococcal vaccine GSK1024850A","otherNames":[]},{"name":"Pneumococcal vaccine GSK1024850A","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects for whom the investigator believes that their parent(s)/ guardian(s) can and will comply with the requirements of the protocol.\n* Written, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nFor primed subjects:\n\n* Completion of the full vaccination course in study NCT00814710.\n* 9-18 months of age at the time of randomization.\n* Group A: 9-18 months of age at the time of booster vaccination.\n* Group B: 15-18 months of age at the time of booster vaccination.\n\nFor unprimed subjects (Group C):\n\n* Enrolled in study NCT00814710.\n* 12-18 months of age at the time of first vaccination.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product within 30 days preceding the vaccination, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.\n* Administration of immunoglobulins and/or any blood products within three months preceding the vaccination or planned administration during the study period.\n* Administration of any pneumococcal vaccine since the end of study NCT00814710.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at the time of enrolment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"9 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes","description":"Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations \\< 0.05 µg/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.78","spread":null},{"groupId":"OG001","value":"5.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"1.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"0.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.28","spread":null},{"groupId":"OG001","value":"11.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":null},{"groupId":"OG001","value":"2.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.86","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null},{"groupId":"OG001","value":"2.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.82","spread":null},{"groupId":"OG001","value":"2.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"7.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.03","spread":null},{"groupId":"OG001","value":"9.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"2.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":null},{"groupId":"OG001","value":"1.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.18","spread":null},{"groupId":"OG001","value":"11.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"4.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":null},{"groupId":"OG001","value":"1.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.39","spread":null},{"groupId":"OG001","value":"42.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":null},{"groupId":"OG001","value":"10.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":null},{"groupId":"OG001","value":"1.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.68","spread":null},{"groupId":"OG001","value":"13.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":null},{"groupId":"OG001","value":"4.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null},{"groupId":"OG001","value":"0.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.54","spread":null},{"groupId":"OG001","value":"6.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes","description":"Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations \\< 0.05 µg/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes (Persistence)","description":"Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations \\< 0.05 µg/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.3","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"0.57","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.38","spread":null},{"groupId":"OG002","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.51","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":null},{"groupId":"OG001","value":"0.98","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"0.98","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":null},{"groupId":"OG001","value":"1.37","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":null},{"groupId":"OG001","value":"1.61","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":null},{"groupId":"OG001","value":"1.36","spread":null},{"groupId":"OG002","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null},{"groupId":"OG001","value":"0.64","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Persistence)","description":"OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. Antibody titers \\< 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"15.6","spread":null},{"groupId":"OG002","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"102.8","spread":null},{"groupId":"OG002","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"10.4","spread":null},{"groupId":"OG002","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1162.5","spread":null},{"groupId":"OG001","value":"1551.1","spread":null},{"groupId":"OG002","value":"1186.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430.4","spread":null},{"groupId":"OG001","value":"617.6","spread":null},{"groupId":"OG002","value":"192.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206.4","spread":null},{"groupId":"OG001","value":"166.3","spread":null},{"groupId":"OG002","value":"13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"42.4","spread":null},{"groupId":"OG002","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"531.1","spread":null},{"groupId":"OG002","value":"41.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F","description":"OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. Antibody titers \\< 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1138.3","spread":null},{"groupId":"OG001","value":"2096.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"173.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"101.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3368.8","spread":null},{"groupId":"OG001","value":"7202.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"557.4","spread":null},{"groupId":"OG001","value":"2525.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"452.7","spread":null},{"groupId":"OG001","value":"834.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null},{"groupId":"OG001","value":"90.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1556.6","spread":null},{"groupId":"OG001","value":"1781.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241.4","spread":null},{"groupId":"OG001","value":"287.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1162.5","spread":null},{"groupId":"OG001","value":"1539.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7814.8","spread":null},{"groupId":"OG001","value":"11064.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2891.2","spread":null},{"groupId":"OG001","value":"5371.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430.4","spread":null},{"groupId":"OG001","value":"704.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4440","spread":null},{"groupId":"OG001","value":"7870.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1926.1","spread":null},{"groupId":"OG001","value":"3504.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206.4","spread":null},{"groupId":"OG001","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2057.1","spread":null},{"groupId":"OG001","value":"4407.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"668.5","spread":null},{"groupId":"OG001","value":"1641.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1889.7","spread":null},{"groupId":"OG001","value":"3643.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233.6","spread":null},{"groupId":"OG001","value":"1155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1672.9","spread":null},{"groupId":"OG001","value":"2404.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.3","spread":null},{"groupId":"OG001","value":"357.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"498.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3812.3","spread":null},{"groupId":"OG001","value":"5937.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1994.1","spread":null},{"groupId":"OG001","value":"3018.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F","description":"OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. Antibody titers \\< 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"309.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2256.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"959.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2946.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"348.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"201.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"740.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1106.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7462.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6295.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5792.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3463.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2359.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1293.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3709.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2487.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2546.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8814.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1768.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"753.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3808.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3378.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1868.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4357.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Persistence)","description":"Antibodies assessed for this outcome measure were those against cross-reactive pneumococcal serotypes 6A and 19A (ANTI-6A and -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations \\< 0.05 µg/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.22","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":null},{"groupId":"OG001","value":"0.33","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"Antibodies assessed for this outcome measure were those against the cross-reactive pneumococcal serotypes 6A and 19A (ANTI-6A and -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations \\< 0.05 µg/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":null},{"groupId":"OG001","value":"0.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":null},{"groupId":"OG001","value":"2.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null},{"groupId":"OG001","value":"1.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"Antibodies assessed for this outcome measure were those against cross-reactive pneumococcal serotypes 6A and 19A (ANTI-6A and -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations \\< 0.05 µg/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Persistence)","description":"OPA titers against cross-reactive pneumococcal serotypes 6A and 19A (Opsono-6A and -19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. Antibody titers \\< 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"30.1","spread":null},{"groupId":"OG002","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"7.4","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"OPA titers against cross-reactive pneumococcal serotypes 6A and 19A (Opsono-6A and -19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. Antibody titers \\< 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168.7","spread":null},{"groupId":"OG001","value":"262.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161.6","spread":null},{"groupId":"OG001","value":"385.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Cross-reactive Pneumococcal Serotypes 6A and 19A","description":"OPA titers against cross-reactive pneumococcal serotypes 6A and 19A (Opsono-6A and -19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8. Antibody titers \\< 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"616.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"506.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"402.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1770.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (Anti-PD) (Persistence)","description":"Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL. Antibody concentrations \\< 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"776.3","spread":null},{"groupId":"OG001","value":"618.6","spread":null},{"groupId":"OG002","value":"71.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (Anti-PD)","description":"Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL. Antibody concentrations \\< 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"776.3","spread":null},{"groupId":"OG001","value":"654.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3704.2","spread":null},{"groupId":"OG001","value":"5297.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1337.3","spread":null},{"groupId":"OG001","value":"2191.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (Anti-PD)","description":"Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL. Antibody concentrations \\< 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"527.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"443.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1727.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (\\>) 30 millimeters (mm). \"Any\" is defined as incidence of the specified symptom regardless of intensity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were Drowsiness, Irritability/Fussiness (Irr./Fuss.), Loss of appetite (Loss Appet.) and Fever (rectal temperature higher than \\[≥\\] 38.0 degrees Celsius \\[°C\\]),. Any = Occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal everyday activities. Grade 3 Irr./Fuss. = Crying that could not be comforted/prevented normal everyday activities. Grade 3 Loss of appetite = Subject did not eat at all. Grade 3 Fever = Rectal temperature higher than (\\>) 40.0°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life- threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Pain","Fever (≥38°C)","Swelling","Irritability","Redness"]}}}